Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis

[1]  T. Kawaguchi,et al.  Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  T. Kawaguchi,et al.  Gut microbiota composition associated with hepatic fibrosis in non‐obese patients with non‐alcoholic fatty liver disease , 2021, Journal of gastroenterology and hepatology.

[3]  H. Møller,et al.  Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis , 2021, Frontiers in Medicine.

[4]  H. El‐Serag,et al.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.

[5]  S. Mogawer,et al.  Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[6]  S. Abd-Elsalam,et al.  MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers , 2020, Molecular Biology Reports.

[7]  Hashem B. El-Serag,et al.  Epidemiology of Hepatocellular Carcinoma , 2020, Hepatology.

[8]  S. Abd-Elsalam,et al.  Study of Serum Soluble Programmed Death Ligand 1 as a prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. , 2019, Current cancer drug targets.

[9]  A. Gastaldelli,et al.  Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease. , 2019, Journal of hepatology.

[10]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[11]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[12]  A. Bauman,et al.  Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease , 2017, Scandinavian journal of clinical and laboratory investigation.

[13]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[14]  S. Abd-Elsalam,et al.  Study of Dickkopf-1 (DKK-1) Gene Expression in Hepatocellular Carcinoma Patients. , 2017, Journal of clinical and diagnostic research : JCDR.

[15]  B. Bibby,et al.  The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[16]  K. Kodys,et al.  Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10 , 2016, Oncoimmunology.

[17]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[18]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[19]  Jessica L. Mueller,et al.  Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease , 2015, Clinical and Translational Gastroenterology.

[20]  K. Clément,et al.  Macrophage activation marker soluble CD163 and non‐alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery , 2015, Journal of gastroenterology and hepatology.

[21]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[22]  H. Møller,et al.  The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children , 2015, Pediatric obesity.

[23]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  B. Bibby,et al.  Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus , 2015, Endocrine connections.

[25]  A. Diehl,et al.  NAFLD, NASH and liver cancer , 2013, Nature Reviews Gastroenterology &Hepatology.

[26]  L. N. Valenti,et al.  Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. , 2012, International journal of molecular medicine.

[27]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[28]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[29]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[30]  A. Testro,et al.  Toll‐like receptors and their role in gastrointestinal disease , 2009, Journal of gastroenterology and hepatology.

[31]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[32]  P. Wallace,et al.  Endotoxin induces rapid metalloproteinase‐mediated shedding followed by up‐regulation of the monocyte hemoglobin scavenger receptor CD163 , 2002, Journal of leukocyte biology.

[33]  K. Lundbaek,et al.  European Association for the study of diabetes , 1969, Diabetologia.

[34]  Clinical Practice Guidelines on the management of benign liver tumours q European Association for the Study of the Liver ( EASL ) ⇑ , 2016 .

[35]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[36]  S. Moestrup,et al.  Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. , 2002, Blood.